Gene Expression Profiling Reveals New Vulnerabilities in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the pleura, characterized by a poor prognosis and resistance to conventional therapies. The standard of care for unresectable and advanced MPM includes combination chemotherapy with pemetrexed disodium and cisplatin, yet response rates remain unsatisfactory, with a median survival time of only about 12 months [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0]. The mechanistic basis for this limited efficacy is not fully understood, but emerging evidence suggests that DNA repair pathways, particularly homologous recombination repair (HRR), may play a crucial role in modulating therapeutic response.

Borchert et al. (2019) aimed to test whether profiling gene expression signatures associated with 'BRCAness'—a phenotype defined by defective HRR similar to BRCA1/2-mutant cancers—could identify MPM tumors likely to respond to poly(ADP-ribose) polymerase (PARP) inhibition. Specifically, the study explored whether defects in HRR, including mutations in BRCA-associated protein 1 (BAP1), sensitize MPM cells to the PARP inhibitor olaparib, alone or in combination with standard chemotherapy [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0].

Key Innovation from the Reference Study

The central innovation of this study is the application of transcriptome-wide gene expression profiling to stratify MPM cases based on HRR pathway integrity. By focusing on the BRCAness phenotype—including, but not limited to, BRCA1/2 mutations—the authors extend the concept of synthetic lethality to a wider subset of mesothelioma cases. They demonstrate that BAP1-deficient and HRR-compromised MPM cells exhibit enhanced sensitivity to PARP inhibition, suggesting a precision oncology approach for this otherwise recalcitrant cancer subtype [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0].

Methods and Experimental Design Insights

Borchert et al. employed an integrative approach combining in vitro drug testing with transcriptomic analysis of clinical samples:

• Cell Line Experiments: Three human MPM cell lines, each with distinct HRR gene status, and normal lung fibroblasts as controls were treated with pemetrexed, cisplatin, and olaparib, both as single agents and in combination.
• Gene Expression Profiling: Digital screening of 91 clinical MPM samples was performed to assess the expression of 91 genes implicated in HRR and BRCAness. Particular attention was paid to BAP1 status and related alterations.
• Functional Readouts: Apoptosis and senescence were measured following drug treatments to determine the impact of HRR status on treatment susceptibility.
• Prognostic Marker Identification: Levels of Aurora Kinase A (AURKA), RAD50, and DNA damage-binding protein 2 (DDB2) were analyzed as potential prognostic indicators.

Protocol Parameters

• assay | Cell viability (apoptosis/MTT) | 0.0001–30 μM pemetrexed, 72 h | applicable to in vitro MPM and tumor cell lines | Standardized for antiproliferative agent in tumor cell lines | product_spec [source_link: https://www.apexbt.com/pemetrexed.html]
• assay | Olaparib + cisplatin combination | variable, per cell line | MPM models with BAP1 mutations | Synergistic induction of apoptosis in HRR-deficient cells | paper [source_link: https://doi.org/10.1186/s12885-019-5314-0]
• assay | Gene expression profiling (digital PCR/microarray) | N/A | Identification of HRR/BRCAness signatures in patient samples | Stratification for susceptibility to PARP inhibition | paper [source_link: https://doi.org/10.1186/s12885-019-5314-0]

Core Findings and Why They Matter

The authors report that approximately 10% of MPM patient samples exhibit a BRCAness gene expression signature, implicating defective HRR as a common event in this malignancy [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0]. Functionally, BAP1-mutated MPM cell lines responded with increased apoptosis and senescence to olaparib, particularly when combined with cisplatin. These effects were not seen in HRR-proficient or control fibroblast lines, supporting a synthetic lethality mechanism. Notably, gene expression levels of AURKA, RAD50, and DDB2 correlated with prognosis, providing potential biomarkers for future stratification.

Importantly, BAP1 loss-of-function mutations—present in 26–64% of MPMs—emerged as a strong predictor of olaparib sensitivity. The study thus proposes that a significant subset of mesothelioma patients may benefit from PARP inhibitor-based regimens, expanding precision medicine opportunities beyond classical BRCA-mutant contexts [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0].

Comparison with Existing Internal Articles

Several internal resources have explored pemetrexed’s role in cancer chemotherapy research, particularly as a multi-targeted antifolate antimetabolite and a TS DHFR GARFT inhibitor:

• Pemetrexed as a Precision Antifolate dissects the drug’s synergy with DNA repair vulnerabilities, aligning closely with Borchert et al.’s focus on exploiting HRR defects in MPM for therapeutic gain.
• Pemetrexed Disodium as a Translational Linchpin addresses translational strategies in non-small cell lung carcinoma and malignant mesothelioma research, emphasizing the importance of understanding gene expression contexts for optimizing antifolate efficacy.
• Pemetrexed as a Precision Research Tool highlights how integration of antifolate agents with synthetic lethality models accelerates discovery of new vulnerabilities—echoing the reference study’s rationale for targeting HRR-compromised tumors.

Collectively, these resources reinforce the translational relevance of combining antifolate chemotherapy with DNA repair-targeted therapies and validate the utility of gene expression profiling in designing rational combination regimens.

Limitations and Transferability

While Borchert et al. provide compelling in vitro and transcriptomic evidence, several limitations warrant consideration. Firstly, the findings are primarily based on cell lines and retrospective patient sample analysis; prospective clinical validation is needed to confirm the predictive value of BRCAness profiling for PARP inhibitor sensitivity in vivo. Secondly, the heterogeneity of HRR pathway alterations in clinical MPM underscores the need for robust, standardized assays for patient selection. Finally, the study did not explore the full range of possible drug combinations or resistance mechanisms that may emerge in the clinical setting [source_type: paper][source_link: https://doi.org/10.1186/s12885-019-5314-0].

Nonetheless, the approach is highly transferable to other cancers characterized by HRR defects, and the methodology for integrating gene expression signatures into therapeutic decision-making is broadly applicable across precision oncology research.

Research Support Resources

Researchers interested in modeling DNA repair vulnerabilities or evaluating synergistic chemotherapy regimens in vitro can utilize Pemetrexed (SKU A4390, APExBIO) as a validated antifolate antimetabolite. Its well-characterized activity against multiple enzymes in nucleotide biosynthesis enables robust assessment of antiproliferative effects in tumor cell lines, including those with engineered or endogenous HRR deficiencies [source_type: product_spec][source_link: https://www.apexbt.com/pemetrexed.html]. For further optimization of experimental protocols, researchers are encouraged to integrate gene expression profiling as demonstrated by Borchert et al., facilitating stratification of cell models and maximizing the translational impact of preclinical findings.